Abbott is advancing its medical device manufacturing operations in Kilkenny, Ireland, with a proposed expansion of its facility at the IDA Business and Technology Park.

The company has applied for permission to extend the industrial building by 1,375 square meters, including additional manufacturing floor space, corridors, and service areas. The plans also include changes to the vehicle entrance and parking lot, with site clearance, a new visitor entrance, and additional parking spaces.

Kilkenny Live reports that Abbott is seeking approval for these works and anticipates a decision by February 24, 2026. The expansion would complement the €440 million facility, which officially opened in November 2024 as a global centre of excellence for Abbott’s Diabetes Care business.

The site produces FreeStyle Libre 3 sensors for continuous glucose monitoring, supporting Abbott’s CGM portfolio and pairing with insulin delivery systems via Libre 3 Plus.

The 30,000-square-meter facility employs over 800 people and incorporates sustainable technologies, including six air-to-water heat pumps, nearly 600 rooftop solar panels, and rainwater collection tanks for on-site use. These features highlight Abbott’s commitment to environmentally conscious manufacturing practices while scaling production to meet global demand.

The expansion reflects Abbott’s ongoing investment in Ireland and its strategy to consolidate Kilkenny as a critical node in its global medical device network.

The project will enhance manufacturing capacity, enable process improvements, and maintain the company’s high standards of product quality and operational efficiency.

Abbott continues to strengthen its footprint in Ireland, reinforcing Kilkenny as a strategic hub for next-generation CGM production.

Read the full story to see how Abbott is scaling its Kilkenny operations.

(Photo Credits to Abbott)